C
CRINETICS PHARMACEUTICALS INC
NASDAQ: CRNX (Crinetics Pharmaceuticals, Inc.)
Last update: 4 hours ago51.88
0.56 (1.09%)
| Previous Close | 51.32 |
| Open | 51.00 |
| Volume | 679,988 |
| Avg. Volume (3M) | 1,366,840 |
| Market Cap | 5,318,314,496 |
| Price / Sales | 3.23 |
| Price / Book | 5.08 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2026 |
| Operating Margin (TTM) | -30,860.11% |
| Diluted EPS (TTM) | -3.80 |
| Quarterly Revenue Growth (YOY) | -43.60% |
| Total Debt/Equity (MRQ) | 4.05% |
| Current Ratio (MRQ) | 22.53 |
| Operating Cash Flow (TTM) | -261.57 M |
| Levered Free Cash Flow (TTM) | -155.77 M |
| Return on Assets (TTM) | -20.13% |
| Return on Equity (TTM) | -30.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Crinetics Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
1.1
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 1.13 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.03% |
| % Held by Institutions | 112.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Price T Rowe Associates Inc /Md/ | 30 Sep 2025 | 5,306,248 |
| Janus Henderson Group Plc | 30 Sep 2025 | 3,858,791 |
| Paradigm Biocapital Advisors Lp | 30 Sep 2025 | 2,550,774 |
| Jennison Associates Llc | 30 Sep 2025 | 2,044,734 |
| Point72 Asset Management, L.P. | 30 Sep 2025 | 2,003,333 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 105.00 (Citizens, 102.39%) | Buy |
| Median | 80.00 (54.20%) | |
| Low | 67.00 (Goldman Sachs, 29.14%) | Buy |
| Average | 84.00 (61.91%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 51.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 12 Jan 2026 | 67.00 (29.14%) | Buy | 55.35 |
| Citizens | 08 Jan 2026 | 105.00 (102.39%) | Buy | 53.24 |
| 07 Nov 2025 | 108.00 (108.17%) | Buy | 40.00 | |
| Morgan Stanley | 06 Jan 2026 | 80.00 (54.20%) | Buy | 45.95 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |